Net profit of Innovent Biologics 2019-2022
In 2022, the net profit of Chinese pharmaceutical firm Innovent Biologics Inc. amounted to negative 2.46 billion yuan, increasing from negative 3.14 billion yuan in the year prior. The core products of Innovent Biologics include anti-tumor medicines and drugs treating metabolic disorders and autoimmune diseases.